About Syndax
Syndax is a company based in Waltham (United States) founded in 2005. Syndax has raised $198.29 million across 11 funding rounds from investors including Fidelity Investments, Orbimed and ArrowMark Partners. The company has 270 employees as of December 31, 2024. Syndax offers products and services including Revumenib and Axatilimab. Syndax operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Waltham, United States
- Employees 270 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Syndax Pharmaceuticals, Inc.
-
Annual Revenue
$23.68 M (USD)0as on Dec 31, 2024
-
Net Profit
-$318.76 M (USD)-52.25as on Dec 31, 2024
-
EBITDA
-$339.66 M (USD)-47.72as on Dec 31, 2024
-
Total Equity Funding
$198.29 M (USD)
in 11 rounds
-
Latest Funding Round
$35 M (USD), Post-IPO
Jan 31, 2020
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
270
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Syndax
Syndax is a publicly listed company on the NASDAQ with ticker symbol SNDX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Syndax
Syndax offers a comprehensive portfolio of products and services, including Revumenib and Axatilimab.
Investigates treatments for acute leukemias and genetic mutations.
Targets graft-versus-host disease and pulmonary fibrosis conditions.
People of Syndax
Unlock access to complete
Unlock access to complete
Leadership Team
37 people
Product Management Team
5 people
Legal and Compliance
5 people
Finance and Accounting
5 people
Human Resources and Administration
4 people
Operations Team
3 people
Data Analysis and Operations Team
3 people
Sales and Marketing
2 people
Unlock access to complete
Funding Insights of Syndax
Syndax has successfully raised a total of $198.29M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Syndax
Syndax has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Orbimed and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm that does early stage investments in the US
|
Locked | Locked | Locked |
Investor details for Syndax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Syndax
Investment portfolio details for Syndax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Syndax
Detailed financials for Syndax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Syndax Comparisons
Peer comparison for Syndax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Syndax
Syndax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Syndax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Syndax
Complete news archive for Syndax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syndax
Syndax was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Syndax is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Syndax is a funded company, having raised a total of $198.29M across 11 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Syndax is 270.
Annual revenue of Syndax is $23.68M as on Dec 31, 2024.
Syndax was founded in 2005 and is headquartered in Waltham, United States. Operations are centered in the biotechnology sector, where targeted therapies for oncology are advanced. Entinostat is being developed as a combination treatment for various cancer types, with primary attention given to immunotherapy-responsive tumors such as those in lung cancer, melanoma, and triple-negative breast cancer.
Syndax's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Syndax offers Revumenib and Axatilimab.
Yes, Syndax is publicly traded on NASDAQ under the ticker symbol SNDX.
Syndax has 15 investors. Key investors include Fidelity Investments, Orbimed, ArrowMark Partners, EcoR1, and Jennison Associates.
The ticker symbol of Syndax is SNDX on NASDAQ.